These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 12414782

  • 1. Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer).
    Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, Guédénon A, Meyers WM.
    Clin Diagn Lab Immunol; 2002 Nov; 9(6):1389-91. PubMed ID: 12414782
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice.
    Tanghe A, Adnet PY, Gartner T, Huygen K.
    Infect Immun; 2007 May; 75(5):2642-4. PubMed ID: 17325046
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin.
    Nackers F, Dramaix M, Johnson RC, Zinsou C, Robert A, DE Biurrun Bakedano E, Glynn JR, Portaels F, Tonglet R.
    Am J Trop Med Hyg; 2006 Oct; 75(4):768-74. PubMed ID: 17038709
    [Abstract] [Full Text] [Related]

  • 8. Findings in patients from Benin with osteomyelitis and polymerase chain reaction-confirmed Mycobacterium ulcerans infection.
    Pommelet V, Vincent QB, Ardant MF, Adeye A, Tanase A, Tondeur L, Rega A, Landier J, Marion E, Alcaïs A, Marsollier L, Fontanet A, Chauty A.
    Clin Infect Dis; 2014 Nov 01; 59(9):1256-64. PubMed ID: 25048846
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.
    Fraga AG, Martins TG, Torrado E, Huygen K, Portaels F, Silva MT, Castro AG, Pedrosa J.
    PLoS One; 2012 Nov 01; 7(3):e33406. PubMed ID: 22413022
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for Buruli ulcer, Benin.
    Debacker M, Portaels F, Aguiar J, Steunou C, Zinsou C, Meyers W, Dramaix M.
    Emerg Infect Dis; 2006 Sep 01; 12(9):1325-31. PubMed ID: 17073079
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prospects for vaccine development against Buruli disease.
    Huygen K.
    Expert Rev Vaccines; 2003 Aug 01; 2(4):561-9. PubMed ID: 14711340
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.
    Marsollier L, Deniaux E, Brodin P, Marot A, Wondje CM, Saint-André JP, Chauty A, Johnson C, Tekaia F, Yeramian E, Legras P, Carbonnelle B, Reysset G, Eyangoh S, Milon G, Cole ST, Aubry J.
    PLoS Med; 2007 Feb 01; 4(2):e64. PubMed ID: 17326707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.